Ó³»­´«Ã½

Pınar Özden Eser is a research scientist in the Cancer Program at the Ó³»­´«Ã½ of MIT and Harvard, working under the direction of . She joined the Getz Lab in 2021, and studies genomic determinants of drug resistance in cancer. Her primary project investigates the clinical evolution of gastric and esophageal adenocarcinomas over the course of patient treatment, leveraging longitudinal tumor biopsies and cell-free tumor DNA. The central objective of Eser's research is identifying potential next-line therapeutic targets that may prolong progression-free survival in patients who become refractory to standard-of-care cancer therapies.

Eser's doctoral work was supported by the National Institutes of Health F31 National Research Service Award, and her postdoctoral research was partially funded by the National Library of Medicine Biomedical Informatics and Data Science Fellowship.

Eser holds a Ph.D. in biological and biomedical sciences from Harvard University, and a Master of Biomedical Informatics (MBI) degree from Harvard Medical School. She completed her Ph.D. research at Dana-Farber Cancer Institute under the concurrent mentorship of Pasi Jänne and George Daley, investigating sensitivity to targeted therapy in non-small cell lung cancer. Her M.B.I. research under the guidance of Nils Gehlenborg centered on developing an application to build web-based interactive visualizations of mutational signatures associated with cancer. Prior to joining the Getz Lab, Eser completed postdoctoral research at Dana-Farber Cancer Institute and the Ó³»­´«Ã½'s Cancer Cell Line Factory.